cIMPACT ‐ NOW update 11: Proposal on adaptation of diagnostic criteria for IDH ‐ and H3 ‐wildtype diffuse high‐grade gliomas and for posterior fossa ependymal tumors
Brain Pathology · 2026-01 · 36 (1)
DOI: 10.1111/bpa.70035 ↗Abstract
Abstract The Consortium to Inform Molecular and Practical Approaches to Central Nervous System Tumor Taxonomy (cIMPACT‐NOW) updates provide guidelines for the diagnosis of central nervous system (CNS) tumors and suggestions for future World Health Organization (WHO) classification. Following publication of the fifth edition WHO Classification of CNS Tumors (WHO CNS5) in 2021, the cIMPACT‐NOW working group “Clarification” reviewed WHO CNS5 and prioritized two topics for further elucidation: (a) distinction of Glioblastoma, IDH‐wildtype from Diffuse pediatric‐type high‐grade glioma, H3‐wildtype, and IDH‐wildtype and (b) clarification of subgroups of posterior fossa (PF) ependymal tumors. Recommendations regarding the IDH‐ and H3‐wildtype diffuse high‐grade gliomas include: (1) use caution assigning CNS WHO grade 4 (diagnosis of Glioblastoma, IDH‐wildtype ) to a “ TERT promoter only”, histologically low‐grade, IDH‐wildtype tumor; (2) EGFR gene amplification and +7/−10 chromosome copy number alterations should not be used as solitary defining features for diagnosing high‐grade gliomas as Glioblastoma, IDH‐wildtype in patients
EUVIMED